Supplementary Materials

Supplementary Material for:

Brain-released alarmins and stress response synergize in accelerating atherosclerosis progression after stroke

Stefan Roth, Vikramjeet Singh, Steffen Tiedt, Lisa Schindler, Georg Huber, Arie Geerlof, Daniel J. Antoine, Antoine Anfray, Cyrille Orset, Maxime Gauberti, Antoine Fournier, Lesca M. Holdt, Helena Erlandsson Harris, Britta Engelhardt, Marco E. Bianchi, Denis Vivien, Christof Haffner, Jürgen Bernhagen, Martin Dichgans, Arthur Liesz*

*Corresponding author. Email: arthur.liesz{at}med.uni-muenchen.de

Published 14 March 2018, Sci. Transl. Med. 10, eaao1313 (2018)
DOI: 10.1126/scitranslmed.aao1313

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Characterization of the 60-min filament MCA occlusion (fMCAo) model.
  • Fig. S2. Exacerbation of atherosclerotic lesions in aortic valves of male and female HCD-fed ApoE−/− mice 1 month after fMCAo surgery.
  • Fig. S3. Immune cell counts in aorta of HCD-fed ApoE−/−; mice 1 month after experimental stroke.
  • Fig. S4. Analysis of atherosclerotic plaque load at the common carotid artery bifurcation in HCD-fed ApoE−/− mice.
  • Fig. S5. Comparison of BrdU incorporation in aorta, blood, and spleen 1 week after experimental stroke surgery.
  • Fig. S6. RFP+CD11b+ cell counts in blood after experimental stroke surgery.
  • Fig. S7. Immunological data of stroke patients.
  • Fig. S8. Body weight and mortality in sRAGE treatment mice after stroke.
  • Fig. S9. Atherosclerotic lesions in aortic valves of male and female HCD-fed ApoE−/− mice 1 month after experimental stroke and sRAGE treatment.
  • Fig. S10. Lipid profile of plasma samples 1 month after experimental stroke surgery and sRAGE treatment.
  • Fig. S11. Flow cytometric analysis of spleen and blood 24 hours after experimental stroke with anti-HMGB1 treatment.
  • Fig. S12. Recombinant HMGB1 in vivo administration exacerbates atherosclerosis.
  • Fig. S13. Quantification of in vivo Qdot labeling of femoral bone marrow 24 hours after experimental stroke.
  • Fig. S14. Myeloid cell count in femoral bone marrow and brain infarct volumetry after splenectomy.
  • Fig. S15. Impact of β3-adrenoreceptor blockage on HMGB1 plasma levels after experimental stroke.
  • Fig. S16. Impact of β3-adrenoreceptor blockage (SR59230A), alarmin blockage (sRAGE), and combined treatment on blood immune cells in WT mice.
  • Fig. S17. Schematic overview of proposed mechanism of atheroprogression after stroke.
  • Table S1. Primer list for quantitative PCR array (mouse chemokines and receptors).
  • Table S2. Demographic and clinical characteristics of the study population.
  • Table S3. Number of (excluded/included) animals in accomplished experiments.
  • References (4149)

[Download PDF]